The 2nd U.S. Circuit Court of Appeals granted a preliminary injunction forcing Actavis to keep selling Namenda IR, an Alzheimer’s drug taken twice a day.
Actavis had planned to pull the drug and replace it with Namenda XR, which is taken once a day. The state of New York alleged the move was meant to stifle competition from generics in violation of antitrust laws. By the time generic versions of the old drug were expected to become available in July, doctors and patients wouldn’t want to switch to them because of the convenience of taking the drug once, not twice a day, New York alleged.